$60.14
Value $7.7B
TXG and UNH stock compared: price, dividend, valuation and results, from SEC filings.
$60.14
Value $7.7B
$326.54
Value $296B
10x Genomics (TXG) has a market value of $7.7B and UnitedHealth (UNH) $296B. Over the last year, with dividends, TXG moved +286.6% and UNH +6.9%. Dividend yield: TXG none, UNH 2.77%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
TXG$7.7B
UNH$296B
UNH is 39 times TXG
Revenue, 12 months
TXG$619M
UNH$450B
UNH is 727 times TXG
Net income, 12 months
TXG-$67M
UNH$15.9B
Operating margin
TXG-11.7%
UNH5.3%
17.0 points apart
ROIC
TXG-7.0%
UNH11.3%
18.3 points apart
P/E
TXG–
UNH18.7
Dividend yield
TXG0.0%
UNH2.8%
2.8 points apart
5-year return
TXG-59.8%
UNH-20.5%
39.3 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
TXG-59.8%
UNH-20.5%
| Period | TXGWith dividends | UNHWith dividends |
|---|---|---|
| 1 year since November 18, 2025 | +286.6%Price +286.6% | +6.9%Price +4.1% |
| 3 years since November 17, 2023 | +42.6%+12.6% a yearPrice +42.6% | -35.2%-13.4% a yearPrice -39.1% |
| 5 years since November 18, 2021 | -59.8%-16.7% a yearPrice -59.8% | -20.5%-4.5% a yearPrice -27.4% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
TXG10x GenomicsUNHUnitedHealth
| Price | $60.14 | $326.54 |
|---|---|---|
| Market value | $7.7B | $296B |
| Enterprise value (EV) | $7.1B | $342B |
| P/E | – | 18.7 |
| P/E, 5-year median | – | 25.0 |
| P/B | 9.2 | 2.9 |
| EV/EBIT | – | 14.3 |
| Free cash flow yield | 1.2% | 7.7% |
| Revenue, 12 months | $619M | $450B |
|---|---|---|
| Net income, 12 months | -$67M | $15.9B |
| Free cash flow, 12 months | $94M | $22.8B |
| Earnings per share, 12 months | -$0.52 | $17.52 |
| Revenue growth, year on year | 5.3% | 11.8% |
| Revenue growth a year, past | +16.6%over 5 years | +11.7%over 5 years |
| EPS growth a year, past | – | -3.8%over 5 years |
| Gross margin | 71.9% | 88.3% |
|---|---|---|
| Operating margin | -11.7% | 5.3% |
| Net margin | -10.8% | 3.5% |
| ROIC | -7.0% | 11.3% |
| ROE | -8.3% | 15.5% |
| Cash | $576M | $28.5B |
|---|---|---|
| Total debt | $76M | $74.3B |
| Net debt / EBITDA | – | 1.6 |
| Interest cover | – | 6.2× |
| Dividend yield | – | 2.8% |
|---|---|---|
| Dividend per share, 12 months | – | $9.06 |
| Dividend growth a year, past | – | +12.6%over 5 years |
| Buyback yield | – | 1.9% |
| Shareholder yield | – | 4.6% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, UnitedHealth ($296B) is about 38.6 times 10x Genomics ($7.7B), at today's prices.
Since November 18, 2021, TXG's price moved -59.8% and UNH's -27.4%. With dividends: TXG -59.8% (-16.7% a year), UNH -20.5% (-4.5% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for 10x Genomics and 2.77% for UnitedHealth. Over the last twelve months they paid – and $9.06 per share.
Over the last twelve months, the net margin was -10.8% for 10x Genomics and 3.5% for UnitedHealth, and the operating margin -11.7% and 5.3%. Revenue was $619M and $450B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.